

## Disclosures

### Personal Commercial (11)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Boehringer Ingelheim-Lilly	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
DalCor	Other - Stock Options	None (\$0)	General Cardiology
DalCor	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
GlaxoSmithKline	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Novartis	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Novartis	Research/Research Grants ‡ PARADISE MI (Chair Executive Ctmd; PARAGON (Steering Cmte Member)	Significant (>= \$5,000)	General Cardiology
Novartis	Other - Patent awarded to BWH regarding the use of inhibitors of the renin-angiotensin system in MI. Licensed by Novartis, Dr. Pfeffer's share irrevocably assigned to charity	None (\$0)	General Cardiology
Novo Nordisk Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Peerbridge	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Sanofi-Aventis	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (3)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
NHLBI CONNECTs	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
UpToDate	Other	Modest (< \$5,000)	General Cardiology
WebMD	Other - Member of Steering Cmte for "Emergence of A New Era for HF Management." Moderator for an Audio/Visual Media :Clinical Dilemmas in HF: What the New Guidelines did not tell us."	Modest (< \$5,000)	General Cardiology

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 10/18/2021

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/18/2021

**Embargo** | Signed on 10/18/2021

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

**On-Going Obligation Agreement** | Signed on 10/18/2021

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.